Boehringer Ingelheim’s landmark first approval for an interchangeable biosimilar monoclonal antibody raises the question “if in the long run, interchangeable biosimilars will be the only biosimilars” for such class of biologics, posits Bernstein Research’s Ronny Gal.
Late last week, the US Food and Drug Administration granted a designation of interchangeability for the German firm’s Cyltezo (adalimumab-adbm) biosimilar of AbbVie’s Humira reference product
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?